echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Medical Supplies Market Risk Analysis Brief - Vascular Intervention Supplies.

    Medical Supplies Market Risk Analysis Brief - Vascular Intervention Supplies.

    • Last Update: 2020-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Vascular interventional supplies refer to the high-value supplies used in vascular intervention surgery, using puncture needles, wire guides, catheters and other consumables through vascular channels to import them into the lesions site for minimally invasive treatment, according to the treatment site can be divided into: cardiovascular intervention supplies, cerebrovascular intervention supplies and outer vascular intervention supplies.
    Cardiovascular interventional supplies include coronary stents, PTCA balloon dilation catheters, catheter guide tubes, etc.; cerebrovascular intervention supplies include cervical artery stents, cone artery stents, intracranial vascular stents, etc.; and weekly vascular interventional consumables include aortic cladding stents, titer artery stents, under-clerical artery stents and renal arterial stents.
    Institute of Medical Research analyzed the market size of vascular intervention supplies market in 2018 is about 38.9 billion yuan, of which the market size of cardiovascular intervention is about 26.4 billion yuan, cerebrovascular intervention market size is about 4.8 billion yuan, and the market size of outer blood vessel intervention is about 7.7 billion yuan.
    according to the National Cardiovascular Center's China Cardiovascular Report (2018), the prevalence of cardiovascular disease in China is on the rise, with an estimate of 290 million cardiovascular diseases, of which 13 million are strokes and coronary heart disease. 11 million diseases, 5 million pulmonary heart disease, 4.5 million heart failure, 2.5 million wind heart disease, 2 million congenital heart disease, high blood pressure 245 million, cardiovascular disease has become a major public health problem in China.
    vascular intervention is a very important technical means in the treatment of cardiovascular diseases, with the advantages of minimally invasive, fast, safe and effective, rapid development in recent years, is currently the most mature market segment, Lepu Medical, Minimally Invasive Medical, Jiwei Medical, Medtrol, Abbott and Boston Scientific Large companies occupy 80% of the market share, local enterprises market share of more than 70%, such as domestic heart stent processing and drug coating and other process technology close to the international advanced level, in stent design, size specifications and the integration of stent and conveyor system more adapted to domestic clinical needs, and the price is lower than imports.
    China's cerebrovascular intervention and external blood vessel intervention market started late, products by Medtron, Johnson and Johnson, Poco-based foreign enterprises occupy more than 90% of the market, only minimally invasive medical, health technology and other possession of a small number of markets.
    1. The General Office of the State Council issued the Notice on the Reform Program for the Management of High-Value Medical Supplies on July 31, 2019, clearly proposing specific requirements for reducing the inflated price of high-value medical supplies, eliminating the increase in medical supplies for medical supplies in public medical institutions, encouraging medical institutions to jointly conduct volume negotiations and procurement, and strictly investigating and punishing clinical violations of high-value medical supplies in various medical institutions at all levels.
    Health insurance directly dominates centralized procurement, the provincial and municipal health insurance departments actively participate in the policy formulation and implementation of centralized procurement, the integration of pricing, collection and payment functions at all levels of health insurance bureaus have been established, health insurance and centralized procurement policies more closely combined.
    addition, DRGs, the health-care payment method centered on pay-per-disease, has prompted hospitals to curb drug abuse while bargaining more dynamic.
    2. The proportion of research and development expenses of enterprises with insufficient investment in research and development is relatively low overall, but in the year-on-year increase (Figure 1), the proportion of research and development revenue of listed companies, with Synjian technology research and development revenue ratio being the highest, was above 20% in 2018 and 2019, and the proportion of research and development expenses of minimally invascopic medical enterprises increased to 19.09 percent in 2019.
    . The basic material is short board, whether in medical metal materials, or biological medical materials, the domestic development is relatively backward.
    But the performance of the material determines the performance of the final implant, the number of domestic high-quality implant-grade raw materials suppliers is very small, the current domestic suppliers of medical metal materials are Seth Mai titanium industry, Bao titanium group, Shenyang Metal Institute, Baoji Xinno, NORD metal, etc., international medical metal materials suppliers mainly have Carpenter and Allegheny, etc., foreign biomedical materials companies are mainly Belang Medical, Bayer, Johnson and Johnson, Medtron, Abbott, Instron, Ceramtec, Ticona, Metallurgical, CRS, Anderen and so on.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.